Company intelligence / Profile preview
Formosa Pharmaceuticals
Taipei City, Taiwanformosapharma.com ↗
- Ownership
- Public · 6838
- Development stage
- Other
01
Overview
Formosa Pharmaceuticals’ lead product APP13007 (clobetasol propionate ophthalmic nanosuspension) received FDA approval in 2024 for post-operative inflammation and pain following ocular surgery. Two Phase 3 trials showed rapid and sustained clearance of inflammation and pain relief superior to placebo. The company has shipped its first commercial batch to the US via partner Eyenovia. Other pipeline assets include a Kadcyla biosimilar for HER2-positive breast cancer in clinical development and additional programs targeting infectious eye diseases and oncology indications.
- Therapeutic areas
- OphthalmologyOncology
- Modalities
- Small moleculesbiosimilars (antibody-drug conjugates)nanoparticle formulations
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Eyenovia Inc. – exclusive US commercialization/licensing partner for APP13007 ($86M deal)AimMax Therapeutics – co-development of clobetasol propionate ophthalmic suspensionApotex Inc., Saval Corporation, Cipla Ltd., Medvisis Switzerland – regional licensing partners for clobetasol suspension
04
Financials
- Market cap
- $117.3M
- Enterprise value
- $117.3M
Beyond the preview
Go deeper on Formosa Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Formosa Pharmaceuticals.